NanoViricides Granted Approval too Initiate Phase II clinical Trial for MPox treatment in the Democratic Republic of Congo
Kinshasa, democratic Republic of Congo – [Date of Original Release] – NanoViricides, Inc. today announced receipt of approval from ACOREP, the regulatory agency of the Democratic Republic of Congo (DRC), to commence a Phase II clinical trial evaluating NV-387 as a treatment for MPox (monkeypox). The trial will be conducted in the DRC, a region significantly impacted by the recent global MPox outbreak.
NV-387 is a nanoviricide, a novel class of antiviral therapeutics developed by NanoViricides. Preclinical studies have demonstrated the potential of NV-387 to neutralize the MPox virus. This Phase II trial will assess the safety and preliminary efficacy of NV-387 in MPox patients.
“We are pleased to receive ACOREP’s approval to initiate this important clinical trial,” stated[Name/Title-[Name/Title-[Name/Title-[Name/Title-information not provided in source]. ”MPox continues to be a public health concern, and we believe NV-387 has the potential to offer a much-needed treatment option, particularly in regions like the DRC where access to healthcare resources may be limited.”
The company notes that the terms “safety” and “effectiveness,” as used in this context,reflect research findings and customary research usage,and do not represent formal evaluation or approval by the US Food and Drug governance (FDA).
About nanoviricides, Inc.
NanoViricides is a biopharmaceutical company developing novel, broad-spectrum antiviral therapies based on it’s nanoviricide technology platform. The company’s research and advancement (R&D) efforts focus on addressing significant unmet medical needs in infectious diseases.
Contact:
NanoViricides,Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
SOURCE: NanoViricides, Inc.
